$CGNT (Cogentix Medical, Inc.)

$CGNT {{ '2016-09-08T12:09:29+0000' | timeago}} • Announcement

$CGNT said it signed a deal with Accelmed Growth Partners, under which Accelmed would buy $25MM of $CGNT common stock at $1.55 per share, a 29% premium over closing price on Sept. 6. Company will use the proceeds for working capital as well as to implement business development strategy to acquire growth technologies in the urology market.

$PG {{ '2017-10-20T19:57:21+0000' | timeago}} • Webcast

$PG still expects majority of EPS growth for 2018 to be driven by operating and earnings growth. The 1Q18 was a little bit more challenging, due to run up of commodity cost and the impact of the natural disasters. The productivity savings will build as $PG grows through the fiscal year and will also began annualizing pricing reductions investment.

$PG {{ '2017-10-20T19:46:37+0000' | timeago}} • Webcast

$PG expects to grow China Baby Care sales this fiscal year and return Pampers to share growth which would mark a significant turnaround. $PG continues to build share in ecommerce in China. $PG grew ecommerce sales about 60% in 1Q18 and a market growing around 50% with 7 out of 10 categories holding growing online market share.

$PG {{ '2017-10-20T19:43:52+0000' | timeago}} • Webcast

For FY18, $PG planned to deliver another year of 90% or better free cash flow productivity. This includes capital expenditures of 5-5.5% of sales. $PG continues its strong track record of cash return to shareholders. $PG expects to pay nearly $7.5Bil in dividends and repurchase $4-7Bil of its shares in FY18.

$PG {{ '2017-10-20T19:38:31+0000' | timeago}} • Webcast

$PG's results for 1Q18 includes about a 30 basis point impacts from the earthquake in Mexico and hurricanes in Texas to Gulf Coast and Puerto Rico. They also include a 40 basis point impact from the combination of U.S. pricing investments and discontinued brands of product forms. $PG said all of these impacts will dissipate as the year progresses.

$PG {{ '2017-10-20T12:44:20+0000' | timeago}} • Infographic

$PG The Procter & Gamble Co. Earnings AlphaGraphic: Q1 2018 Highlights

$PG {{ '2017-10-20T11:47:55+0000' | timeago}} • Announcement

$PG maintained its core EPS growth expectation of 5-7% versus FY17 Core EPS of $3.92. This is despite over $100MM of incremental commodity cost headwinds resulting from the hurricanes that impacted the Gulf Coast in September. All-in GAAP EPS are expected to decrease 26-28% versus 2017 GAAP EPS of $5.59.

$PG {{ '2017-10-20T11:45:58+0000' | timeago}} • Announcement

$PG maintained its guidance for organic sales growth in the range of 2-3% for FY18. The company estimates all-in sales growth of about 3% for FY18, which includes a neutral to half-a-percentage-point benefit to sales growth from the combined impacts of foreign exchange, acquisitions and divestitures.

$PG {{ '2017-10-20T11:44:44+0000' | timeago}} • Announcement

$PG's gross margin for 1Q18 decreased 40 basis points. On a currency-neutral basis, core gross margin fell 10 points as 150 points of productivity savings were more than offset by 70 points of commodity cost rises, 50 points of unfavorable geographic and product mix and 40 points of product reinvestments and other impacts.

$PG {{ '2017-10-20T11:41:13+0000' | timeago}} • Announcement

$PG's Baby, Feminine and Family Care segment organic sales for 1Q18 declined 1% from the prior year. Baby Care organic sales decreased mid-single digits due in part to competitive activity in Europe and a decline in China Baby Care shipments due primarily to wholesaler inventory run-down ahead of new innovation shipments.

$PG {{ '2017-10-20T11:40:58+0000' | timeago}} • Announcement

$PG's Health Care segment organic sales for 1Q18 rose 1%. Oral Care organic sales increased low single digits behind product innovation on power toothbrushes and toothpaste and increased marketing support. Personal Health Care organic sales slid low single digits on lower volume.

$PG {{ '2017-10-20T11:40:39+0000' | timeago}} • Announcement

$PG's grooming segment organic sales for 1Q18 fell 6% on lower sales in Shave Care. Organic sales slid high single digits in Shave Care due to price reductions in the U.S. and negative product mix. Organic sales rose double digits in Appliances on increased volume from the continued success of innovation on Braun male styling and mid-tier shavers.

$PG {{ '2017-10-20T11:40:23+0000' | timeago}} • Announcement

$PG's beauty segment organic sales for 1Q18 increased 5% from a year ago. Organic sales were up double digits in Skin & Personal Care on growth in China, including the continued acceleration of the super-premium SK-II brand. Organic sales increased low single digits in Hair Care on increased pricing across regions behind product innovation.

$PG {{ '2017-10-20T11:40:11+0000' | timeago}} • Announcement

$PG reported a 5% rise in 1Q18 earnings on lower interest expense, higher interest income and a rise in non-operating income. Net income grew to $2.85Bil or $1.06 per share from $2.71Bil or $0.96 per share last year. Net sales rose 0.8% to $16.65Bil. Core EPS increased to $1.09 from $1.03. Organic sales rose 1% on higher shipment volume.

$JNJ {{ '2017-10-17T19:25:16+0000' | timeago}} • Webcast

$JNJ said, "The key factor to Remicade being successful is physicians and patients have a high confidence in it based on experience that they don't want to switch to an alternative." The company was responding to a question on rival $PFE's lawsuit against it for allegedly using unfair means to protect Remicade from competitors.

$MYL {{ '2017-10-17T16:40:23+0000' | timeago}} • Announcement

$MYL announced that the United States District Court for the Eastern District of Texas issued a decision finding all asserted claims of the patents relating to Restasis invalid. The Court recognized that $AGN's patent protection for Restasis ended in 2014.

$AGN {{ '2017-10-16T21:26:34+0000' | timeago}} • Announcement

Drugmaker $AGN gets an adverse effect from the U.S. District Court for the Eastern District of Texas. The judge invalidated Allergan's Restasis patent deal, which was signed with the Mohawk Tribe in the last month. Allergan plans to appeal the ruling. Restasis, a dry-eye treatment drug,  generated $1.5Bil of revenues for Allergan in 2016.

$AGN {{ '2017-10-12T22:44:22+0000' | timeago}} • Announcement

$AGN, which inked a controversial patent deal with Mohawk Tribe, reached a patent litigation settlement on its dry eye treatment drug Restasis with InnoPharma, a unit of $PFE. The litigation, which was filed in Sept. 2015 by Allergan, will be withdrawn and Allergan will grant license to InnoPharma to market Restasis from Feb. 2024 or earlier.

$AGN {{ '2017-10-10T18:02:39+0000' | timeago}} • Announcement

FDA accepts to review $AGN's New Drug Application seeking approval for ulipristal acetate, an investigational drug for the treatment of abnormal bleeding in women with uterine fibroids. Allergan expects the action date to occur in 1H18. According to the Agency for Healthcare Research and Quality (AHRQ), 26MM women in U.S. have got uterine fibroids.

$PG {{ '2017-10-10T16:14:25+0000' | timeago}} • Announcement

$PG's shareholders have voted to elect all 11 of its highly qualified Directors to its Board. Nelson Peltz of Trian was not elected to the Board. This is based on a preliminary vote count provided by its proxy solicitors following its 2017 Annual Meeting.

$EBS {{ '2017-10-03T13:27:49+0000' | timeago}} • Announcement

Life sciences firm $EBS completed the acquisition of raxibacumab, an FDA-approved human monoclonal antibody for the treatment of inhalational anthrax, from $GSK. The company plans a $130MM contract with the Biomedical Advanced Research and Development Authority to supply the product to the US Strategic National Stockpile through November 2019.

Recent Transcripts

PG (The Procter & Gamble Company)
Friday, October 20 2017 - 12:30pm
INFO (IHS Markit Ltd.)
Tuesday, September 26 2017 - 12:00pm
ABEO (Abeona Therapeutics Inc.)
Tuesday, August 22 2017 - 2:00pm
APPS (Digital Turbine, Inc.)
Monday, August 7 2017 - 8:30pm
AINC (Ashford, Inc.)
Friday, August 4 2017 - 4:00pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
FIT (Fitbit Inc.)
Wednesday, August 2 2017 - 9:00pm
VVV (Valvoline Inc.)
Wednesday, August 2 2017 - 3:00pm
CGNT (Cogentix Medical, Inc.)
Tuesday, August 1 2017 - 8:30pm
PFE (Pfizer Inc.)
Tuesday, August 1 2017 - 2:00pm
PG (The Procter & Gamble Company)
Thursday, July 27 2017 - 12:30pm
GSK (GlaxoSmithKline plc)
Wednesday, July 26 2017 - 1:00pm
AMD (Advanced Micro Devices, Inc.)
Tuesday, July 25 2017 - 9:00pm
NVS (Novartis AG)
Tuesday, July 18 2017 - 12:00pm
AGN (Allergan plc)
Tuesday, May 9 2017 - 12:30pm
AINC (Ashford, Inc.)
Friday, May 5 2017 - 4:00pm
FIT (Fitbit Inc.)
Wednesday, May 3 2017 - 9:00pm
CGNT (Cogentix Medical, Inc.)
Tuesday, May 2 2017 - 8:30pm
PFE (Pfizer Inc.)
Tuesday, May 2 2017 - 2:00pm
AMD (Advanced Micro Devices, Inc.)
Monday, May 1 2017 - 9:00pm

AlphaGraphics you may like